Fig. 2.

Cardiac function assessed by echocardiography in conscious mice 2 wk after vehicle or angiotensin II (ANG II; 1.4 mg·kg⁻¹·day⁻¹) ± daily injections of L798,106 (40 µg·kg⁻¹·day⁻¹) or diluted ethanol vehicle control. Ejection fraction (EF; A), shortening fraction (SF; B), posterior wall thickness at systole (PWT_s; C), and cardiac output (CO; D) are shown. **P < 0.01, ***P < 0.005 vs. vehicle; +P < 0.05, +++P < 0.005 vs. ANG II. n = 11–13 Mice. E: heart weight (HW)-to-body weight (BW) ratio. Mice were anesthetized, and hearts were removed, weighed, and presented as milligrams per 10 g body wt. *P < 0.05 vs. vehicle. F: systolic blood pressure measured by tail-cuff plethysmography in conscious mice at baseline and 1 and 2 wk after vehicle or ANG II (1.4 mg·kg⁻¹·day⁻¹) ± daily injections of L798,106 (40 µg·kg⁻¹·day⁻¹) or diluted ethanol vehicle control for 2 wk. ***P < 0.005 vs. vehicle, +P < 0.05 vs. ANG II. n = 11–13 Mice per group. G: mean arterial pressure (MAP) measured in the carotid artery 2 wk after vehicle or ANG II (1.4 mg·kg⁻¹·day⁻¹) ± daily injections of L798,106 (40 µg·kg⁻¹·day⁻¹) or diluted ethanol vehicle. *P < 0.05 vs. vehicle, ++P < 0.01 vs. ANG II. n = 4–8 Mice per group. For statistical analysis, a 2-sample Wilcoxon test with the Fligner–Policello correction for unequal variances was used. To correct for multiple testing, we used Hochberg correcting method.